Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

The innovation, he says, could transform the way scientists measure and address genomic breaks in gene-editing systems.

By creating gene editors not found in nature, or optimizing existing editors, AI can improve the accuracy, effectiveness, and accessibility of gene editing.

Encasing CRISPR tools in oil droplets offers a fast-track approach to conducting extensive genetic screens in animals.

Potent in vivo gene editing in skeletal muscle of non-human primates by a novel, ultracompact CRISPR system delivered via a single AAV vector.

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...

One sickle cell patient told ITV News the new gene therapy being rolled out for use on the NHS means they "finally have something to look towards". | ITV National News ...

Overnight DeepSeek is the role model of the startup ecosystem. It is demonstrating real-time to every business, idea, or ...

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November, ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...